An αvβ6-specific virotherapy expressing bispecific immune cell activators induces immune cell activation to mediate...

Area of Science:

• Oncolytic Virotherapy
• Immunotherapy
• Cancer Therapeutics

Background:

• Ad5_NULL-A20 is an adenovirus type 5-based precision virotherapy targeting αvβ6-positive tumors.
• Bispecific immune cell activators (BICAs) enhance tumor-specific immune responses by engaging immune cells and tumor antigens.
• Combining these approaches aims for a potent, localized immune response with reduced toxicity.

Purpose of the Study:

• To develop and evaluate Ad5_NULL-A20 expressing BICAs for enhanced cancer immunotherapy.
• To create a novel therapeutic strategy combining oncolytic virotherapy with targeted immune activation.

Main Methods:

• Development of multiple BICAs targeting T cells (CD3) and NK cells (CD16/NKG2D) against tumor-associated antigens (EGFR, MICA).
• In vitro assessment of Ad5_NULL-A20 BICA efficacy on αvβ6 tumor cells, evaluating immune cell activation and tumor cell viability.
• Ex vivo validation using patient-derived 3D tumor organoids treated with Ad5_NULL-A20-BICA and immune cells (T cells or NK cells).

Main Results:

• In vitro studies demonstrated T cell and NK cell activation at tumor sites and reduced tumor cell viability.
• Ex vivo studies showed significant and rapid reduction in the growth of patient-derived tumor organoids.
• Ad5_NULL-A20-BICA induced potent immune responses, leading to tumor eradication in experimental models.

Conclusions:

• Ad5_NULL-A20 expressing BICAs can generate potent, tumor-specific immune responses.
• This combined approach shows significant translational potential for developing novel cancer therapeutics.
• The strategy promises improved tolerability and efficacy by localizing immune responses to tumor sites.